Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FFOoUiRqbeuRbh1bk1fdox4EPZDI.uncropped.jpg&w=3840&q=75)
Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- ChecktodayChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.0%
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe website has been updated from version v2.10.0 to v2.10.2.SummaryDifference0.0%
- Check28 days agoNo Change Detected
- Check41 days agoChange DetectedA new resource titled 'Helpful Links Provided by Andrea Ardizzoni' has been added, featuring information on Cabozantinib (XL184), highlighting its role as a novel MET and VEGFR2 inhibitor that suppresses metastasis, angiogenesis, and tumor growth.SummaryDifference0.6%
- Check43 days agoChange DetectedThe study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check50 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check61 days agoChange DetectedThe website has removed information about Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, and helpful links provided by Andrea Ardizzoni from the University of Bologna.SummaryDifference0.6%
Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.